ResearcherThe University of TokyoActive in the last 2 years
Hideo Yasunaga
Matched on ORCID iD 0000-0002-6017-469X; OpenAlex author ID A5076707735. Sources: OpenAlex.
Their work
- Papers
- 5 (first author 0, last author 2)
- Trials
- 0
- Grants
- 0
- Labs led
- 1
- Collaborators
- 13
2014: 1 paper · 2015: none · 2016: 1 paper · 2017: none · 2018: none · 2019: none · 2020: none · 2021: none · 2022: none · 2023: 1 paper · 2024: none · 2025: 2 papers
Papers 5
- Association of comorbid schizophrenia with cancer stage at admission, treatments, length of stay, and 30-day in-hospital mortality in patients with pancreatic … Last author DOI 10.1016/j.ejca.2025.115468↗
- Corrigendum to "Association of comorbid schizophrenia with cancer stage at admission, treatments, length of stay, and 30-day in-hospital mortality in patients … Last author DOI 10.1016/j.ejca.2025.115495↗
- Gemcitabine plus nab-paclitaxel for pancreatic cancer and interstitial lung disease: A nationwide longitudinal study. Co-author DOI 10.1111/cas.15910↗
- Progression-free survival as a surrogate for overall survival in first-line chemotherapy for advanced pancreatic cancer. Co-author DOI 10.1016/j.ejca.2016.05.016↗
- Prognostic nomogram for nonresectable pancreatic cancer treated with gemcitabine-based chemotherapy. Co-author DOI 10.1038/bjc.2014.131↗
Closest collaborators
The 13 strongest of 13 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Jiashiang Lin · 2 shared papers, 2025 · strength 0.61
- Paper Association of comorbid schizophrenia with cancer stage at admission, treatments, length of stay, and 30-day in-hospita… DOI 10.1016/j.ejca.2025.115468↗
- Paper Corrigendum to "Association of comorbid schizophrenia with cancer stage at admission, treatments, length of stay, and 3… DOI 10.1016/j.ejca.2025.115495↗
- Tsuyoshi Hamada · 3 shared papers, 2014–2023 · strength 0.27
- Paper Gemcitabine plus nab-paclitaxel for pancreatic cancer and interstitial lung disease: A nationwide longitudinal study. DOI 10.1111/cas.15910↗
- Paper Progression-free survival as a surrogate for overall survival in first-line chemotherapy for advanced pancreatic cancer. DOI 10.1016/j.ejca.2016.05.016↗
- Paper Prognostic nomogram for nonresectable pancreatic cancer treated with gemcitabine-based chemotherapy. DOI 10.1038/bjc.2014.131↗
- Yousuke Nakai · 3 shared papers, 2014–2023 · strength 0.27
- Paper Gemcitabine plus nab-paclitaxel for pancreatic cancer and interstitial lung disease: A nationwide longitudinal study. DOI 10.1111/cas.15910↗
- Paper Progression-free survival as a surrogate for overall survival in first-line chemotherapy for advanced pancreatic cancer. DOI 10.1016/j.ejca.2016.05.016↗
- Paper Prognostic nomogram for nonresectable pancreatic cancer treated with gemcitabine-based chemotherapy. DOI 10.1038/bjc.2014.131↗
- Kei Saito · 1 shared paper, 2023 · strength 0.18
- Mitsuhiro Fujishiro · 1 shared paper, 2023 · strength 0.18
- Minoru Tada · 2 shared papers, 2014–2016 · strength 0.09
- Naminatsu Takahara · 2 shared papers, 2014–2016 · strength 0.09
- Hirofumi Kogure · 2 shared papers, 2014–2016 · strength 0.09
- Hiroyuki Isayama · 2 shared papers, 2014–2016 · strength 0.09
- Kazuhiko Koike · 2 shared papers, 2014–2016 · strength 0.09
- Suguru Mizuno · 1 shared paper, 2016 · strength 0.05
- Saburo Matsubara · 1 shared paper, 2016 · strength 0.05
- Takashi Sasaki · 1 shared paper, 2014 · strength 0.03
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.